The gap between what medicine can do and what actually happens remains wide.
Medicine has largely answered the question of whether a mother living with HIV can protect her child from the virus — under proper care, transmission falls below 2 percent. Yet children continue to be born with HIV, not because the science has failed, but because the systems that carry science into human lives remain uneven and fragile. A new research supplement from the Journal of the International AIDS Society, assembled by scholars across three continents, turns its attention to this gap — not the gap in knowledge, but the gap between what is possible and what is actually happening in clinics, villages, and overburdened health systems around the world.
- The medical breakthrough is real: vertical HIV transmission has been reduced to below 2% when treatment is consistently maintained — yet children are still being born with the virus every day.
- Three stubborn obstacles keep the gap open: mothers struggling to maintain daily antiretroviral adherence, women who arrive late to care or learn of their HIV status only at labor, and health systems in resource-limited regions too fragile to deliver consistent treatment.
- A special JIAS supplement published in mid-2026 — co-edited by researchers from the United States, Brazil, and Zimbabwe — frames this as unfinished business, signaling that the global AIDS community is shifting its focus from discovery to delivery.
- The hardest questions now are not scientific but structural: how to sustain adherence across years of treatment, how to reach women earlier in pregnancy, and how to build reliable care infrastructure where it is most needed and least present.
The science has largely solved mother-to-child HIV transmission. When pregnant women living with HIV receive and maintain antiretroviral treatment, the virus passes to their babies less than 2 percent of the time — not in theory, but in practice, when the systems work. Yet children continue to be born with HIV, and the distance between what medicine can achieve and what actually unfolds remains wide.
In mid-2026, the Journal of the International AIDS Society released a special supplement titled "Unfinished Business in Elimination of Vertical HIV Transmission and Ensuring HIV-Free Survival." Its three editors — Lynne Mofenson at the Elizabeth Glaser Pediatric AIDS Foundation, Jorge Pinto at the Federal University of Minas Gerais in Brazil, and Angela Mushavi from Zimbabwe's Ministry of Health — span continents, and their collaboration reflects the scope of a problem that belongs to no single region.
Three obstacles define what remains undone. The first is adherence: staying on medication daily, through pregnancy and beyond, while navigating stigma, side effects, and the logistics of care, is genuinely hard. The second is late presentation — women who learn they are pregnant or HIV-positive only near delivery, compressing months of standard prevention into hours. The third is geography: in wealthy countries, vertical transmission is nearly extinct; in resource-limited settings across Africa, Asia, and Latin America, fragile supply chains, undertrained personnel, and strained infrastructure make consistent care elusive.
The supplement marks a shift in the conversation. The question is no longer whether transmission can be prevented — it can. The question is why it still happens, and what it will take to close the distance between the achievable and the actual.
The science has largely solved the problem of mother-to-child HIV transmission. When pregnant women living with HIV receive antiretroviral treatment and stay on it, the virus passes to their babies less than 2 percent of the time. That is not a theoretical achievement—it is what happens in practice when the systems work. Yet across the world, children continue to be born with HIV, and the gap between what medicine can do and what actually happens remains wide.
The Journal of the International AIDS Society released a special supplement in mid-2026 to examine this paradox. Titled "Unfinished Business in Elimination of Vertical HIV Transmission and Ensuring HIV-Free Survival," the collection was assembled by three editors working across continents: Lynne Mofenson at the Elizabeth Glaser Pediatric AIDS Foundation in the United States, Jorge Pinto at the Federal University of Minas Gerais in Brazil, and Angela Mushavi, who leads the AIDS and TB Unit within Zimbabwe's Ministry of Health. Their collaboration itself signals the scope of the problem—it is not confined to one region or one health system, but woven through the fabric of global public health.
The progress has been real. Decades of research in maternal and pediatric HIV have transformed what was once a near-certain transmission into a preventable event. The numbers tell that story plainly: when adequate care is provided and people adhere to their medications, vertical transmission drops below 2 percent. This is not a marginal improvement. It is the difference between an epidemic and its containment.
But the supplement exists because the story does not end there. Three persistent obstacles block the path to elimination. The first is maternal adherence to antiretroviral treatment. Staying on medication every day, for years, through pregnancy and beyond, is not a simple task. Women face stigma, side effects, the logistics of accessing pills, the burden of managing their own health while preparing for a child. Getting pregnant women to take their medications reliably remains one of the hardest problems in prevention.
The second obstacle is late presentation. Some women do not know they are pregnant until late in pregnancy, or do not know they are living with HIV until labor begins. By then, the window for prevention has narrowed. The virus has had months to replicate, and the standard interventions—months of maternal treatment, intravenous medication during delivery, infant prophylaxis—must be compressed into days or hours.
The third is geography and resources. In wealthy countries with robust health systems, vertical transmission is nearly extinct. In resource-limited settings—parts of Africa, Asia, and Latin America where the burden of HIV is heaviest—the infrastructure to deliver consistent care, the trained personnel to manage complex pregnancies, and the supply chains to ensure medications are available remain fragile. Health disparities are not accidental; they are baked into the systems themselves.
What the supplement signals is that the conversation has shifted. The question is no longer whether vertical transmission can be prevented. It is why it still happens, and what it will take to close the gap between the possible and the actual. The editors and contributors are asking hard questions about adherence support, about how to reach pregnant women early, about how to build health systems in places where resources are scarce. These are not questions that have simple answers, but they are the questions that matter now.
Citas Notables
Eliminating vertical transmission remains a global public health priority, and significant challenges persist in optimizing maternal adherence to antiretroviral treatment, managing late-presenting pregnancies and addressing health disparities in resource-limited settings.— Journal of the International AIDS Society supplement editors
La Conversación del Hearth Otra perspectiva de la historia
The science works—sub-2 percent transmission when people take their medication. So why does the supplement exist at all?
Because knowing something works in a trial and making it work for every pregnant woman are two entirely different things. The supplement is asking: what happens in the real world, where women are poor, where clinics are understaffed, where stigma is real?
You're saying the problem isn't medical anymore.
Exactly. The medicine solved the medical problem. What remains is everything else—getting women to take pills every day, finding them before they go into labor, building health systems that can actually deliver care where it's needed.
Late presentation seems like it should be easier to solve than adherence. Just screen more women earlier.
In theory, yes. But screening requires access to clinics, trust in the health system, knowledge that you might be at risk. In resource-limited settings, those things aren't guaranteed. And even when women are found early, keeping them engaged in care through pregnancy is its own challenge.
So the three editors—they're from the US, Brazil, and Zimbabwe. Is that deliberate?
It has to be. The problem looks different in each place. What works in a wealthy country's health system won't transplant directly to somewhere with a fraction of the resources. The supplement is trying to learn from all three contexts at once.
What comes next? After this supplement, what actually changes?
That's the harder question. The supplement names the problems clearly. Whether health systems have the will and resources to solve them—that's what happens in the years ahead.